mechlorethamine has been researched along with Cutaneous T-Cell Lymphoma in 31 studies
nitrogen mustard : Compounds having two beta-haloalkyl groups bound to a nitrogen atom, as in (X-CH2-CH2)2NR.
| Excerpt | Relevance | Reference |
|---|---|---|
| "To study the exact frequency and the histological features of cutaneous intolerance to mechlorethamine (CIM) hydrochloride therapy in patients with cutaneous T-cell lymphomas, including Langerhans cell histiocytosis." | 7.70 | A prospective study of cutaneous intolerance to topical mechlorethamine therapy in patients with cutaneous T-cell lymphomas. French Study Group of Cutaneous Lymphomas. ( Avril, MF; Bagot, M; Beylot-Barry, M; Delaunay, M; Estève, E; Grange, F; Joly, P; Laroche, L; Souteyrand, P; Thomine, E; Vaillant, L; Wechsler, J, 1999) |
| " Six of these patients showed allergic contact dermatitis to mechlorethamine after a mean period of 9." | 5.10 | Evaluation of a 1-h exposure time to mechlorethamine in patients undergoing topical treatment. ( Dalac, S; Delaunay, M; Dréno, B; Evrard, V; Foulc, P; Guillot, B; Verret, JL, 2002) |
| " The additional use of mechlorethamine or oral psoralen plus UV-A, but not radiation, was significantly associated with the development of basal cell carcinoma and squamous cell carcinoma, but not malignant melanoma." | 4.79 | Malignant melanoma and other second cutaneous malignancies in cutaneous T-cell lymphoma. The influence of additional therapy after total skin electron beam radiation. ( Braverman, IM; Feldman, AM; Kacinski, BM; Licata, AG; Wilson, LD, 1995) |
| "The two major topical treatment modalities for cutaneous T-cell lymphoma (CTCL) are mechlorethamine (nitrogen mustard) and topical carmustine (BCNU)." | 4.79 | Topical treatment of early cutaneous T-cell lymphoma. ( Meller, JA; Ramsay, DL; Zackheim, HS, 1995) |
| "To study the exact frequency and the histological features of cutaneous intolerance to mechlorethamine (CIM) hydrochloride therapy in patients with cutaneous T-cell lymphomas, including Langerhans cell histiocytosis." | 3.70 | A prospective study of cutaneous intolerance to topical mechlorethamine therapy in patients with cutaneous T-cell lymphomas. French Study Group of Cutaneous Lymphomas. ( Avril, MF; Bagot, M; Beylot-Barry, M; Delaunay, M; Estève, E; Grange, F; Joly, P; Laroche, L; Souteyrand, P; Thomine, E; Vaillant, L; Wechsler, J, 1999) |
| " CL gel has a manageable safety profile, with most adverse events being mild and skin related." | 2.82 | Chlormethine Gel for Patients with Mycosis Fungoides Cutaneous T Cell Lymphoma: A Review of Efficacy and Safety in Clinical Trial and Real-World Settings. ( Ardigò, M; Nikbakht, N; Papadavid, E; Querfeld, C; Wehkamp, U, 2022) |
| " US Food and Drug Administration (FDA)-approved, oral systemic bexarotene has the advantage of a 48% overall response rate at a dosage of 300 mg/m(2)/day, and avoids immunosuppression and risk of central line and catheter-related infectious complications that are associated with other systemic therapies." | 2.41 | Treatment of cutaneous T cell lymphoma: current status and future directions. ( Apisarnthanarax, N; Duvic, M; Talpur, R, 2002) |
| " Chlormethine gel could be combined with other skin-directed or systemic therapies for optimal benefit." | 1.62 | Chlormethine Gel in Combination with Other Therapies in the Treatment of Patients with Mycosis Fungoides Cutaneous T Cell Lymphoma: Three Case Reports. ( Karagianni, F; Koumourtzis, M; Lampadaki, K; Marinos, L; Papadavid, E, 2021) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 12 (38.71) | 18.2507 |
| 2000's | 9 (29.03) | 29.6817 |
| 2010's | 4 (12.90) | 24.3611 |
| 2020's | 6 (19.35) | 2.80 |
| Authors | Studies |
|---|---|
| Correia, E | 1 |
| Krishnasamy, S | 1 |
| Suriano, JG | 1 |
| Shi, W | 1 |
| Alpdogan, SO | 1 |
| Sahu, J | 1 |
| Porcu, P | 1 |
| Nikbakht, N | 2 |
| Wehkamp, U | 1 |
| Ardigò, M | 1 |
| Papadavid, E | 2 |
| Querfeld, C | 3 |
| Gniadecki, R | 1 |
| Paron, E | 1 |
| Lampadaki, K | 1 |
| Koumourtzis, M | 1 |
| Karagianni, F | 1 |
| Marinos, L | 1 |
| Cortes, JR | 1 |
| Patrone, CC | 1 |
| Quinn, SA | 1 |
| Gu, Y | 1 |
| Sanchez-Martin, M | 1 |
| Mackey, A | 1 |
| Cooke, AJ | 1 |
| Shih, BB | 1 |
| Laurent, AP | 1 |
| Trager, MH | 1 |
| Ferrando, AA | 1 |
| Geskin, LJ | 2 |
| Palomero, T | 1 |
| Scarisbrick, JJ | 1 |
| Assaf, C | 1 |
| Guenova, E | 1 |
| Bagot, M | 2 |
| Ortiz-Romero, PL | 1 |
| Quaglino, P | 1 |
| Bonizzoni, E | 1 |
| Hodak, E | 1 |
| Jawed, SI | 1 |
| Myskowski, PL | 1 |
| Horwitz, S | 1 |
| Moskowitz, A | 1 |
| Dulmage, BO | 1 |
| Story, SK | 1 |
| Falo, LD | 1 |
| Ritschel, WA | 1 |
| Ye, W | 1 |
| Buhse, L | 1 |
| Reepmeyer, JC | 1 |
| Momtaz, P | 1 |
| Zippin, JH | 1 |
| Poligone, B | 1 |
| Heald, P | 1 |
| Foulc, P | 1 |
| Evrard, V | 1 |
| Dalac, S | 1 |
| Guillot, B | 1 |
| Delaunay, M | 2 |
| Verret, JL | 1 |
| Dréno, B | 1 |
| Bachelez, H | 1 |
| Hultgren, TL | 1 |
| Jones, D | 1 |
| Duvic, M | 4 |
| Licata, AG | 1 |
| Wilson, LD | 1 |
| Braverman, IM | 1 |
| Feldman, AM | 1 |
| Kacinski, BM | 1 |
| Zackheim, HS | 3 |
| Bunn, PA | 1 |
| Jörg, B | 1 |
| Kerl, H | 1 |
| Thiers, BH | 1 |
| Bröcker, EB | 1 |
| Burg, G | 1 |
| Young, JW | 1 |
| Ramsay, DL | 1 |
| Meller, JA | 1 |
| Vonderheid, EC | 1 |
| Ekbote, SK | 1 |
| Kerrigan, K | 1 |
| Kalmanson, JD | 1 |
| Van Scott, EJ | 1 |
| Rook, AH | 1 |
| Abrams, JT | 1 |
| Estève, E | 1 |
| Joly, P | 1 |
| Souteyrand, P | 1 |
| Beylot-Barry, M | 1 |
| Vaillant, L | 1 |
| Avril, MF | 1 |
| Laroche, L | 1 |
| Grange, F | 1 |
| Thomine, E | 1 |
| Wechsler, J | 1 |
| Muche, JM | 1 |
| Gellrich, S | 1 |
| Sterry, W | 1 |
| Apisarnthanarax, N | 1 |
| Talpur, R | 1 |
| Holloway, KB | 1 |
| Flowers, FP | 1 |
| Ramos-Caro, FA | 1 |
| Smith, SP | 1 |
| Konnikov, N | 1 |
| Springer, EA | 1 |
| Kuzel, TM | 1 |
| Rosen, ST | 1 |
| Roenigk, HH | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Phase II Pivotal Trial to Evaluate the Safety and Efficacy of Nitrogen Mustard (NM) 0.02% Ointment Formulations in Patients With Stage I or IIA Mycosis Fungoides (MF)[NCT00168064] | Phase 2 | 260 participants (Actual) | Interventional | 2006-05-31 | Completed | ||
| Treatments and Outcomes in Patients With Primary Cutaneous Lymphoma: a Nationwide Multi-center Prospective Study in China[NCT05518851] | 3,000 participants (Anticipated) | Observational | 2022-08-01 | Recruiting | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Assessment of lesion distribution and severity. A responder analysis was performed on whether subject achieved at least 50% improvement on scale. This had to be confirmed on at least one visit at least 4 weeks apart. (NCT00168064)
Timeframe: Baseline to end of therapy
| Intervention | Percent of participants (Number) |
|---|---|
| PG -Mechlorethamine-MCH (Nitrogen Mustard) 0.02% PG Gel | 61 |
| AP- Mechlorethamine-MCH (NM) 0.02% Compounded in Aquaphor | 60 |
The ratio of the response rate of the patients treated with the PG formulation to the response rate of the patients treated with the AP formulation. Skin response determined by at least a 50% reduction from baseline in the Composite Assessment of Index Lesion Severity (CAILS) following up to 12 months of treatment (NCT00168064)
Timeframe: Assessment made at Day 1 and every subsequent visit during treatment
| Intervention | percentage of participants (Number) |
|---|---|
| PG- Mechlorethamine-MCH (Nitrogen Mustard) 0.02% Gel | 76 |
| AP- Aquaphor Formulation Mechlorethamine-MCH (NM) 0.02% | 62 |
16 reviews available for mechlorethamine and Cutaneous T-Cell Lymphoma
| Article | Year |
|---|---|
Chlormethine Gel for Patients with Mycosis Fungoides Cutaneous T Cell Lymphoma: A Review of Efficacy and Safety in Clinical Trial and Real-World Settings.
Topics: Clinical Trials as Topic; Gels; Humans; Lymphoma, T-Cell, Cutaneous; Mechlorethamine; Mycosis Fungoi | 2022 |
Primary cutaneous T-cell lymphoma (mycosis fungoides and Sézary syndrome): part II. Prognosis, management, and future directions.
Topics: Administration, Cutaneous; Adrenal Cortex Hormones; Combined Modality Therapy; Dermatologic Agents; | 2014 |
In brief: mechlorethamine gel (Valchlor) for cutaneous T-Cell lymphoma.
Topics: Administration, Cutaneous; Animals; Antineoplastic Agents, Alkylating; Gels; Humans; Lymphoma, T-Cel | 2015 |
Cutaneous T-cell lymphoma: a review of current therapies and the future therapeutic implications of chemokine biology.
Topics: Administration, Cutaneous; Adrenal Cortex Hormones; Chemokines; Humans; Lymphoma, T-Cell, Cutaneous; | 2009 |
Innovative therapy of cutaneous T-cell lymphoma: beyond psoralen and ultraviolet light and nitrogen mustard.
Topics: Aminoquinolines; Combined Modality Therapy; Cryotherapy; Histone Deacetylase Inhibitors; Humans; Imi | 2010 |
Systemic monotherapy vs combination therapy for CTCL: rationale and future strategies.
Topics: Alemtuzumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Neoplasm; Antine | 2007 |
Malignant melanoma and other second cutaneous malignancies in cutaneous T-cell lymphoma. The influence of additional therapy after total skin electron beam radiation.
Topics: Adult; Aged; Carcinoma, Basal Cell; Carcinoma, Squamous Cell; Electrons; Female; Humans; Lymphoma, T | 1995 |
Treatment of cutaneous T-cell lymphoma.
Topics: Carmustine; Combined Modality Therapy; Humans; Interferon-alpha; Lymphoma, T-Cell, Cutaneous; Mechlo | 1994 |
Therapeutic approaches in cutaneous lymphoma.
Topics: Antineoplastic Agents; Combined Modality Therapy; Humans; Interferon-alpha; Lymphoma, T-Cell, Cutane | 1994 |
Treatment of cutaneous T-cell lymphoma: an update.
Topics: Antineoplastic Agents; Humans; Lymphoma, T-Cell, Cutaneous; Mechlorethamine; Photochemotherapy; Reti | 1993 |
Topical treatment of early cutaneous T-cell lymphoma.
Topics: Administration, Topical; Antineoplastic Agents, Alkylating; Carmustine; History, 20th Century; Human | 1995 |
Cutaneous T cell lymphoma: update of treatment.
Topics: Administration, Topical; Adrenal Cortex Hormones; Antineoplastic Agents, Alkylating; Beta Particles; | 1999 |
Treatment of cutaneous T-cell lymphomas.
Topics: Adjuvants, Immunologic; Administration, Topical; Antibodies, Monoclonal; Antineoplastic Agents; Anti | 2000 |
Current treatment of Cutaneous T-Cell Lymphoma.
Topics: Administration, Oral; Administration, Topical; Anticarcinogenic Agents; Apoptosis; Bexarotene; Biops | 2001 |
Treatment of cutaneous T cell lymphoma: current status and future directions.
Topics: Adrenal Cortex Hormones; Antibodies, Monoclonal; Antineoplastic Agents; Bone Marrow Transplantation; | 2002 |
Therapeutic alternatives in cutaneous T-cell lymphoma.
Topics: Combined Modality Therapy; Humans; Interferons; Lymphoma, T-Cell, Cutaneous; Mechlorethamine; Neopla | 1992 |
2 trials available for mechlorethamine and Cutaneous T-Cell Lymphoma
| Article | Year |
|---|---|
Post hoc Analysis of a Randomized, Controlled, Phase 2 Study to Assess Response Rates with Chlormethine/Mechlorethamine Gel in Patients with Stage IA-IIA Mycosis Fungoides.
Topics: Antineoplastic Agents, Alkylating; Humans; Lymphoma, T-Cell, Cutaneous; Mechlorethamine; Mycosis Fun | 2022 |
Evaluation of a 1-h exposure time to mechlorethamine in patients undergoing topical treatment.
Topics: Administration, Topical; Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Dermatit | 2002 |
13 other studies available for mechlorethamine and Cutaneous T-Cell Lymphoma
| Article | Year |
|---|---|
Response to Chlormethine/Mechlorethamine gel Maintenance Treatment Regimen in Patients With Mycosis Fungoides: A Single-center Retrospective Study.
Topics: Humans; Lymphoma, T-Cell, Cutaneous; Mechlorethamine; Mycosis Fungoides; Retrospective Studies; Skin | 2022 |
Chlormethine Gel for the Treatment of Mycosis Fungoides (Cutaneous T-cell Lymphoma) in Canada.
Topics: Adult; Humans; Lymphoma, T-Cell, Cutaneous; Mechlorethamine; Mycosis Fungoides; Skin; Skin Neoplasms | 2023 |
Chlormethine Gel in Combination with Other Therapies in the Treatment of Patients with Mycosis Fungoides Cutaneous T Cell Lymphoma: Three Case Reports.
Topics: Humans; Lymphoma, T-Cell, Cutaneous; Mechlorethamine; Mycosis Fungoides; Quality of Life; Skin Neopl | 2021 |
Jak-STAT Inhibition Mediates Romidepsin and Mechlorethamine Synergism in Cutaneous T-Cell Lymphoma.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Depsipeptides; Drug Syner | 2021 |
Novel therapeutic combination demonstrates more than additive effects in cutaneous T-cell lymphoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cell Proliferation; Depsipeptides; DNA Damage; Human | 2015 |
Stability of the nitrogen mustard mechlorethamine in novel formulations for dermatological use.
Topics: Administration, Cutaneous; Antineoplastic Agents, Alkylating; Drug Compounding; Drug Delivery System | 2008 |
[Local treatments of cutaneous T-cell lymphomas].
Topics: Administration, Topical; Antineoplastic Agents, Alkylating; Humans; Lymphoma, T-Cell, Cutaneous; Mec | 2005 |
Topical nitrogen mustard for the treatment of granulomatous slack skin.
Topics: Administration, Topical; Adult; Aged; Antineoplastic Agents, Alkylating; Biopsy; Female; Humans; Lym | 2007 |
Cutaneous T cell lymphomas.
Topics: Administration, Topical; Humans; Lymphoma, T-Cell, Cutaneous; Mechlorethamine; Methoxsalen; Randomiz | 1994 |
The prognostic significance of delayed hypersensitivity to dinitrochlorobenzene and mechlorethamine hydrochloride in cutaneous T cell lymphoma.
Topics: Administration, Topical; Adolescent; Adult; Aged; Aged, 80 and over; Dinitrochlorobenzene; Disease P | 1998 |
A prospective study of cutaneous intolerance to topical mechlorethamine therapy in patients with cutaneous T-cell lymphomas. French Study Group of Cutaneous Lymphomas.
Topics: Administration, Cutaneous; Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkyla | 1999 |
Eruptive epidermal cysts and multiple squamous cell carcinomas after therapy for cutaneous T-cell lymphoma.
Topics: Administration, Cutaneous; Carcinoma, Squamous Cell; Epidermal Cyst; Humans; Lymphoma, T-Cell, Cutan | 1991 |
International symposium on cutaneous T cell lymphoma. Chicago, Illinois, Oct. 19-21, 1989.
Topics: Chicago; Humans; Interferon alpha-2; Interferon-alpha; Lymphoma, T-Cell, Cutaneous; Mechlorethamine; | 1991 |